AI Article Synopsis

  • The study aimed to evaluate the economic and health impacts of hospital-acquired venous thromboembolism (VTE) on patients and healthcare systems across ten countries, including Australia and the UK.
  • A mixed-methods approach was used, including surveys with healthcare professionals and a systematic literature review, leading to the identification of five key clinical specialties: orthopedics, oncology, ICU, cardiology, and obstetrics/gynecology.
  • The total estimated cost of hospital-acquired VTE was $41,280 million, affecting patient mortality rates and accounting for 150,081 deaths, highlighting significant implications for healthcare systems.

Article Abstract

Aim: The objective of this study was to assess the burden of hospital-acquired venous thromboembolism (VTE) on healthcare systems and patients across ten countries.

Methods: A multi-methodological approach was taken to estimate the burden of hospital-acquired VTE across five key clinical specialties and ten countries (Australia, Brazil, China, France, Mexico, South Korea, Spain, Taiwan, Thailand, and the United Kingdom). Surveys with healthcare professionals (surgeons, hematologists, and hospital management) were conducted to identify clinical specialties of interest. A systematic literature review and interviews were conducted to identify data for incidences and costs. A health-economic model was developed, using a decision tree and Markov model to estimate 1-year costs. Costs are presented in 2022 USD.

Results: Orthopedics, oncology, long-term ICU, cardiology, and obstetrics and gynecology were identified as the clinical specialties of interest. The total cost burden of hospital-acquired VTE was estimated to be $41,280 million, which equals $503 per patient at risk. Expressed as a share of 2022 GDP, an average spending per country of 0.05% to 0.18% was observed. The VTE-associated mortality was substantial, accounting for 150,081 deaths in a 74.2 million population, translating into an average mortality rate of 2.02 (0.64-3.05) per 1,000 patients at risk.

Limitations: There were limited data available concerning VTE incidences in some countries and clinical specialties. Where data were available, there was heterogeneity of incidence definitions across the identified studies. Generalizations, imputations, and the country-agnostic structure of the model might have contributed to biases.

Conclusions: The burden of hospital-acquired VTE is substantial both from an economic and from a patient perspective in all countries evaluated.

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2024.2436797DOI Listing

Publication Analysis

Top Keywords

burden hospital-acquired
16
clinical specialties
16
hospital-acquired vte
12
venous thromboembolism
8
ten countries
8
markov model
8
conducted identify
8
specialties interest
8
burden
5
vte
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!